Recent Developments in Understanding Brain Aging: Implications for Alzheimer's Disease and Vascular Cognitive Impairment

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 71, Issue 1, 2015, Pages 13-20

  Deak, Ferenc ^a   Freeman, Willard M ^a   Ungvari, Zoltan ^a   Csiszar, Anna ^a   Sonntag, William E ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Alzheimer's disease; Brain aging; Cerebrovasculature

Indexed keywords

AGING; ALZHEIMER DISEASE; BRAIN; CELL AGING; DEMENTIA, VASCULAR; EARLY DIAGNOSIS; EARLY INTERVENTION; HUMAN; METABOLISM; PHYSIOLOGY; PROCEDURES; PROGNOSIS; PSYCHOLOGY;

AGING; ALZHEIMER DISEASE; BRAIN; CELL AGING; DEMENTIA, VASCULAR; EARLY DIAGNOSIS; EARLY MEDICAL INTERVENTION; HUMANS; PROGNOSIS;

EID: 84960497024     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glv206     Document Type: Article

References (128)

1. Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L. gamma-Secretase inhibitors and modulators. Biochim Biophys Acta. 2013;1828:2898-2907. doi:10.1016/j.bbamem.2013.06.005
2. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:311-321. doi:10.1056/NEJMoa1312889
3. Galasko DR, Graff-Radford N, May S, et al. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord. 2007;21:292-299.
4. Siemers ER, Sundell KL, Carlson C, et al. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement. 2015. doi:10.1016/j.jalz.2015.06.1893
5. Andreasen N, Simeoni M, Ostlund H, et al. First administration of the Fcattenuated anti-beta amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study. PLoS One. 2015;10:e0098153. doi:10.1371/journal.pone.0098153
6. Arrighi HM, Barakos J, Barkhof F, et al. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis. J Neurol Neurosurg Psychiatry. 2015 pii: jnnp-2014-309493. doi:10.1136/jnnp-2014-309493
7. Lahiri DK, Maloney B, Long JM, Greig NH. Lessons from a BACE1 inhibitor trial: off-site but not off base. Alzheimers Dement. 2014;10(5 Suppl):S411-S419. doi:10.1016/j.jalz.2013.11.004
8. Golde TE, Schneider LS, Koo EH. Anti-a? therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron. 2011;69:203-213. doi:10.1016/j.neuron.2011.01.002
9. Rembach A, Faux NG, Watt AD, et al. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimers Dement. 2014;10:53-61. doi:10.1016/j.jalz.2012.12.006
10. Randall C, Mosconi L, de Leon M, Glodzik L. Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly. Front Biosci 2013;18:1150-1173.
11. de Leon MJ, Mosconi L, Blennow K, et al. Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci. 2007;1097:114-145. doi:10.1196/annals.1379.012
12. Hampel H, Burger K, Pruessner JC, et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol. 2005;62:770-773. doi:10.1001/archneur.62.5.770
13. Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med. 2013;368:1169-1171. doi:10.1056/NEJMp1302513
14. Seshadri S, Wolf PA, Beiser A, et al. Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study. Neurology. 1997;49:1498-1504.
15. Hua X, Hibar DP, Lee S, et al. Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiol Aging. 2010;31:1463-1480. doi:10.1016/j.neurobiolaging.2010.04.033
16. Holland D, Desikan RS, Dale AM, McEvoy LK; Alzheimer's Disease Neuroimaging I. Higher rates of decline for women and apolipoprotein E epsilon4 carriers. AJNR Am J Neuroradiol. 2013;34:2287-2293. doi:10.3174/ajnr.A3601
17. Banks WA, Abrass CK, Hansen KM. Differentiating the influences of aging and adiposity on brain weights, levels of serum and brain cytokines, gastrointestinal hormones, and amyloid precursor protein. J Gerontol A Biol Sci Med Sci. 2014 doi:10.1093/gerona/glu100 [Epub ahead of print].
18. Koyama A, O'Brien J, Weuve J, Blacker D, Metti AL, Yaffe K. The role of peripheral inflammatory markers in dementia and Alzheimer's disease: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2013;68:433-440. doi:10.1093/gerona/gls187
19. Weiner MW, Veitch DP, Aisen PS, et al. 2014 Update of the Alzheimer's disease neuroimaging initiative: a review of papers published since its inception. Alzheimers Dement. 2015;11:e1-e120. doi:10.1016/j.jalz.2014.11.001
20. Cirrito JR, Kang JE, Lee J, et al. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008;58:42-51.
21. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088-1093.
22. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094-1099. doi:10.1038/ng.439
23. Corneveaux JJ, Myers AJ, Allen AN, et al. Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet. 2010;19:3295-3301. doi:10.1093/hmg/ddq221
24. Kauwe JS, Cruchaga C, Karch CM, et al. Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease. PLoS One. 2011;6:e15918. doi:10.1371/journal.pone.0015918
25. Sevlever D, Zou F, Ma L, et al. Genetically-controlled vesicle-associated membrane protein 1 expression may contribute to Alzheimer's pathophysiology and susceptibility. Mol Neurodegener. 2015;10:18. doi:10.1186/s13024-015-0015-x
26. Zhao Z, Sagare AP, Ma Q, et al. Central role for PICALM in amyloidbeta blood-brain barrier transcytosis and clearance. Nat Neurosci. 2015;18:978-987. doi:10.1038/nn.4025
27. Schoenherr CJ, Anderson DJ. The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science. 1995;267:1360-1363.
28. Lu T, Aron L, Zullo J, et al. REST and stress resistance in ageing and Alzheimer's disease. Nature. 2014;507:448-454. doi:10.1038/nature13163
29. De Ferrari GV, Papassotiropoulos A, Biechele T, et al. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc Natl Acad Sci USA. 2007;104:9434-9439. doi:10.1073/pnas.0603523104
30. Alarcon MA, Medina MA, Hu Q, et al. A novel functional low-density lipoprotein receptor-related protein 6 gene alternative splice variant is associated with Alzheimer's disease. Neurobiol Aging. 2013;34:1709. e9-1709.e18. doi:10.1016/j.neurobiolaging.2012.11.004
31. Liu CC, Tsai CW, Deák F, et al. Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer's disease. Neuron. 2014;84:63-77. doi:10.1016/j.neuron.2014.08.048
32. North BJ, Rosenberg MA, Jeganathan KB, et al. SIRT2 induces the checkpoint kinase BubR1 to increase lifespan. EMBO J. 2014;33:1438-1453. doi:10.15252/embj.201386907
33. De Felice FG, Velasco PT, Lambert MP, et al. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem. 2007;282:11590-11601.
34. Tay WM, Bryant JG, Martin PK, Nix AJ, Cusack BM, Rosenberry TL. A mass spectrometric approach for characterization of amyloid-? aggregates and identification of their post-translational modifications. Biochemistry. 2012;51:3759-3766. doi:10.1021/bi300316d
35. Cho DH, Nakamura T, Fang J, et al. S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science. 2009;324:102-105. doi:10.1126/science.1171091
36. Manczak M, Calkins MJ, Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum Mol Genet. 2011;20:2495-2509. doi:10.1093/hmg/ddr139
37. Yan J, Liu XH, Han MZ, et al. Blockage of GSK3beta-mediated Drp1 phosphorylation provides neuroprotection in neuronal and mouse models of Alzheimer's disease. Neurobiol Aging. 2015;36:211-227. doi:10.1016/j. neurobiolaging.2014.08.005
38. Sheng M, Sabatini BL, Sudhof TC. Synapses and Alzheimer's disease. Cold Spring Harb Perspect Biol. 2012;4(5):371-388. doi:10.1101/cshperspect. a005777.
39. Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs. 2003;17:27-45.
40. Freiherr J, Hallschmid M, Frey WH II, et al. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs. 2013;27:505-514. doi:10.1007/s40263-013-0076-8
41. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012;69:29-38. doi:10.1001/archneurol.2011.233
42. Morris JK, Burns JM. Insulin: an emerging treatment for Alzheimer's disease dementia? Curr Neurol Neurosci Rep. 2012;12:520-527. doi: 10.1007/s11910-012-0297-0
43. De Felice FG, Vieira MN, Bomfim TR, et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci USA. 2009;106:1971-1976.
44. Maimaiti S, Anderson KL, DeMoll C, et al. Intranasal insulin improves age-related cognitive deficits and reverses electrophysiological correlates of brain aging. J Gerontol A Biol Sci Med Sci. 2015 pii: glu314 [Epub ahead of print]
45. Garcia-Mesa Y, Colie S, Corpas R, et al. Oxidative stress is a central target for physical exercise neuroprotection against pathological brain aging. J Gerontol A Biol Sci Med Sci. 2015 pii: glv005 [Epub ahead of print].
46. Hampstead BM, Stringer AY, Stilla RF, et al. Activation and effective connectivity changes following explicit-memory training for face-name pairs in patients with mild cognitive impairment: a pilot study. Neurorehabil Neural Repair. 2011;25:210-222. doi:10.1177/1545968310382424
47. Hosseini SM, Kramer JH, Kesler SR. Neural correlates of cognitive intervention in persons at risk of developing Alzheimer's disease. Front Aging Neurosci. 2014;6:231. doi:10.3389/fnagi.2014.00231
48. Suthana N, Haneef Z, Stern J, et al. Memory enhancement and deep-brain stimulation of the entorhinal area. N Engl J Med. 2012;366:502-510. doi:10.1056/NEJMoa1107212
49. Laxton AW, Tang-Wai DF, McAndrews MP, et al. A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Ann Neurol. 2010;68:521-534. doi:10.1002/ana.22089
50. Laxton AW, Lipsman N, Lozano AM. Deep brain stimulation for cognitive disorders. Handb Clin Neurol. 2013;116:307-311. doi:10.1016/B978-0-444-53497-2.00025-5
51. Telese F. Keystone symposia on neuroepigenetics-bridging the gap between genome and behavior. Neuroepigenetics. 2015;2:9-12.
52. Spiegel AM, Sewal AS, Rapp PR. Epigenetic contributions to cognitive aging: disentangling mindspan and lifespan. Learn Mem. 2014;21:569-574. doi:10.1101/lm.033506.113
53. Hannum G, Guinney J, Zhao L, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell. 2013;49:359-367. doi:10.1016/j.molcel.2012.10.016
54. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14:R115. doi:10.1186/gb-2013-14-10-r115
55. Weidner CI, Lin Q, Koch CM, et al. Aging of blood can be tracked by DNA methylation changes at just three CpG sites. Genome Biol. 2014;15:R24. doi:10.1186/gb-2014-15-2-r24
56. Johnson AA, Akman K, Calimport SR, Wuttke D, Stolzing A, de Magalhães JP. The role of DNA methylation in aging, rejuvenation, and age-related disease. Rejuvenation Res. 2012;15:483-494. doi:10.1089/rej.2012.1324
57. Waki H, Yamauchi T, Kadowaki T. The epigenome and its role in diabetes. Curr Diab Rep. 2012;12:673-685. doi:10.1007/s11892-012-0328-x
58. Horvath S, Mah V, Lu AT, et al. The cerebellum ages slowly according to the epigenetic clock. Aging (Albany NY). 2015;7:294-306.
59. Cho SH, Chen JA, Sayed F, et al. SIRT1 deficiency in microglia contributes to cognitive decline in aging and neurodegeneration via epigenetic regulation of IL-1beta. J Neurosci. 2015;35:807-818. doi:10.1523/JNEUROSCI.2939-14.2015
60. Lister R, Mukamel EA, Nery JR, et al. Global epigenomic reconfiguration during mammalian brain development. Science. 2013;341:1237905. doi:10.1126/science.1237905
61. Kozlenkov A, Roussos P, Timashpolsky A, et al. Differences in DNA methylation between human neuronal and glial cells are concentrated in enhancers and non-CpG sites. Nucleic Acids Res. 2014;42:109-127. doi:10.1093/nar/gkt838
62. Zentner GE, Henikoff S. High-resolution digital profiling of the epigenome. Nat Rev Genet. 2014;15:814-827. doi:10.1038/nrg3798
63. Bock C. Analysing and interpreting DNA methylation data. Nat Rev Genet. 2012;13:705-719. doi:10.1038/nrg3273
64. Springo Z, Tarantini S, Toth P, et al. Aging exacerbates pressure-induced mitochondrial oxidative stress in mouse cerebral arteries. J Gerontol A Biol Sci Med Sci. 2015;70(11):1355-1359. doi:10.1093/gerona/glu244. Epub January 28, 2015.
65. Toth P, Tarantini S, Springo Z, et al. Aging exacerbates hypertensioninduced cerebral microhemorrhages in mice: role of resveratrol treatment in vasoprotection. Aging Cell. 2015;14:400-408. doi:10.1111/acel.12315
66. Ungvari Z, Sonntag WE. Brain and cerebrovascular aging-new mechanisms and insights. J Gerontol A Biol Sci Med Sci. 2014;69:1307-1310. doi:10.1093/gerona/glu187
67. Tucsek Z, Toth P, Tarantini S, et al. Aging exacerbates obesity-induced cerebromicrovascular rarefaction, neurovascular uncoupling, and cognitive decline in mice. J Gerontol A Biol Sci Med Sci. 2014;69:1339-1352. doi:10.1093/gerona/glu080
68. Carnevale D, Mascio G, D'Andrea I, et al. Hypertension induces brain beta-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension. 2012;60:188-197. doi:10.1161/HYPERTENSIONAHA.112.195511
69. Sagare AP, Bell RD, Zhao Z, et al. Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun. 2013;4:2932. doi:10.1038/ncomms3932
70. Halliday MR, Rege SV, Ma Q, et al. Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. J Cereb Blood Flow Metab. 2015 doi:10.1038/jcbfm.2015.44 [Epub ahead of print].
71. Montagne A, Barnes SR, Sweeney MD, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015;85:296-302. doi:10.1016/j.neuron.2014.12.032
72. Montagne A, Pa J, Zlokovic BV. Vascular plasticity and cognition during normal aging and dementia. JAMA Neurol. 2015;72:495-496. doi:10.1001/jamaneurol.2014.4636
73. Snyder HM, Corriveau RA, Craft S, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement. 2015;11:710-717. doi:10.1016/j.jalz.2014.10.008
74. Sweeney MD, Sagare AP, Zlokovic BV. Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease. J Cereb Blood Flow Metab. 2015;35:1055-1068. doi:10.1038/jcbfm.2015.76
75. Winkler EA, Nishida Y, Sagare AP, et al. GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci. 2015;18:521-530. doi:10.1038/nn.3966
76. Tucsek Z, Toth P, Sosnowska D, et al. Obesity in aging exacerbates bloodbrain barrier disruption, neuroinflammation, and oxidative stress in the mouse hippocampus: effects on expression of genes involved in beta-amyloid generation and Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 2014;69:1212-1226. doi:10.1093/gerona/glt177
77. Banki E, Sosnowska D, Tucsek Z, et al. Age-related decline of autocrine pituitary adenylate cyclase-activating polypeptide impairs angiogenic capacity of rat cerebromicrovascular endothelial cells. J Gerontol A Biol Sci Med Sci. 2015;70:665-674. doi:10.1093/gerona/glu116
78. Ungvari Z, Tucsek Z, Sosnowska D, et al. Aging-induced dysregulation of dicer1-dependent microrna expression impairs angiogenic capacity of rat cerebromicrovascular endothelial cells. J Gerontol A Biol Sci Med Sci. 2013;68:877-891. doi:10.1093/gerona/gls242
79. Csiszar A, Sosnowska D, Tucsek Z, et al. Circulating factors induced by caloric restriction in the nonhuman primate Macaca mulatta activate angiogenic processes in endothelial cells. J Gerontol A Biol Sci Med Sci. 2013;68:235-249. doi:10.1093/gerona/gls158
80. Csiszar A, Gautam T, Sosnowska D, et al. Caloric restriction confers persistent anti-oxidative, pro-angiogenic, and anti-inflammatory effects and promotes anti-aging miRNA expression profile in cerebromicrovascular endothelial cells of aged rats. Am J Physiol Heart Circ Physiol. 2014;307:H292-H306. doi:10.1152/ajpheart.00307.2014
81. Valcarcel-Ares MN, Gautam T, Warrington JP, et al. Disruption of Nrf2 signaling impairs angiogenic capacity of endothelial cells: implications for microvascular aging. J Gerontol A Biol Sci Med Sci. 2012;67:821-829. doi:10.1093/gerona/glr229
82. Lynch CD, Cooney PT, Bennett SA, et al. Effects of moderate caloric restriction on cortical microvascular density and local cerebral blood flow in aged rats. Neurobiol Aging. 1999;20:191-200. S0197458099000329 [pii]
83. Toth P, Tucsek Z, Sosnowska D, et al. Age-related autoregulatory dysfunction and cerebromicrovascular injury in mice with angiotensin IIinduced hypertension. J Cereb Blood Flow Metab. 2013;33:1732-1742. doi:10.1038/jcbfm.2013.143
84. Riddle DR, Sonntag WE, Lichtenwalner RJ. Microvascular plasticity in aging. Ageing Res Rev. 2003;2:149-168. S1568163702000648 [pii]
85. Shen Q, Wang Y, Kokovay E, et al. Adult SVZ stem cells lie in a vascular niche: a quantitative analysis of niche cell-cell interactions. Cell Stem Cell. 2008;3:289-300. doi:10.1016/j.stem.2008.07.026
86. Ungvari Z, Kaley G, de Cabo R, Sonntag WE, Csiszar A. Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci. 2010;65:1028-1041. doi:10.1093/gerona/glq113
87. Nisoli E, Tonello C, Cardile A, et al. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science. 2005;310:314-317.
88. Toth P, Tarantini S, Tucsek Z, et al. Resveratrol treatment rescues neurovascular coupling in aged mice: role of improved cerebromicrovascular endothelial function and down-regulation of NADPH oxidas. Am J Physiol Heart Circ Physiol. 2014;306:H299-H308. doi:10.1152/ajpheart.00744.2013
89. Sagare AP, Bell RD, Zlokovic BV. Neurovascular defects and faulty amyloid-? vascular clearance in Alzheimer's disease. J Alzheimers Dis. 2013;33(suppl 1):S87-S100. doi:10.3233/JAD-2012-129037
90. Zlokovic BV. Neurodegeneration and the neurovascular unit. Nat Med. 2010;16:1370-1371. doi:10.1038/nm1210-1370
91. Csiszar A, Tucsek Z, Toth P, et al. Synergistic effects of hypertension and aging on cognitive function and hippocampal expression of genes involved in beta-amyloid generation and Alzheimer's disease. Am J Physiol Heart Circ Physiol. 2013;305:H1120-H1130. doi:10.1152/ajpheart.00288.2013
92. Park L, Anrather J, Girouard H, Zhou P, Iadecola C. Nox2-derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain. J Cereb Blood Flow Metab. 2007;27:1908-1918. doi:10.1038/sj.jcbfm.9600491
93. Farkas E, Bari F. Spreading depolarization in the ischemic brain: does aging have an impact? J Gerontol A Biol Sci Med Sci. 2014;69:1363-1370. doi:10.1093/gerona/glu066
94. Zaletel M, Strucl M, Pretnar-Oblak J, Zvan B. Age-related changes in the relationship between visual evoked potentials and visually evoked cerebral blood flow velocity response. Funct Neurol. 2005;20:115-120.
95. Topcuoglu MA, Aydin H, Saka E. Occipital cortex activation studied with simultaneous recordings of functional transcranial Doppler ultrasound (fTCD) and visual evoked potential (VEP) in cognitively normal human subjects: effect of healthy aging. Neurosci Lett. 2009; 452:17-22.
96. Stefanova I, Stephan T, Becker-Bense S, Dera T, Brandt T, Dieterich M. Age-related changes of blood-oxygen-level-dependent signal dynamics during optokinetic stimulation. Neurobiol Aging. 2013;34:2277-2286. doi:10.1016/j.neurobiolaging.2013.03.031
97. Sorond FA, Hurwitz S, Salat DH, Greve DN, Fisher ND. Neurovascular coupling, cerebral white matter integrity, and response to cocoa in older people. Neurology. 2013;81:904-909. WNL.0b013e3182a351aa [pii]
98. Sorond FA, Kiely DK, Galica A, et al. Neurovascular coupling is impaired in slow walkers: the MOBILIZE Boston Study. Ann Neurol. 2011;70:213-220. doi: 10.1002/ana.22433
99. Tarantini S, Hertelendy P, Tucsek Z, et al. Pharmacologically-induced neurovascular uncoupling is associated with cognitive impairment in mice. J Cereb Blood Flow Metab. 2015;35(11):1871-1881. doi:10.1038/jcbfm.2015.162
100. Allali G, van der Meulen M, Beauchet O, Rieger SW, Vuilleumier P, Assal F. The neural basis of age-related changes in motor imagery of gait: an fMRI study. J Gerontol A Biol Sci Med Sci. 2014;69:1389-1398. doi:10.1093/gerona/glt207
101. Barak B, Feldman N, Okun E. Cardiovascular fitness and cognitive spatial learning in rodents and in humans. J Gerontol A Biol Sci Med Sci. 2015;70(9):1059-1066. doi:10.1093/gerona/glu162 [Epub September 16, 2014].
102. Buchman AS, Yu L, Wilson RS, Boyle PA, Schneider JA, Bennett DA. Brain pathology contributes to simultaneous change in physical frailty and cognition in old age. J Gerontol A Biol Sci Med Sci. 2014;69:1536-1544. doi:10.1093/gerona/glu117
103. Callisaya ML, Beare R, Phan T, et al. Progression of white matter hyperintensities of presumed vascular origin increases the risk of falls in older people. J Gerontol A Biol Sci Med Sci. 2015;70:360-366. doi:10.1093/gerona/glu148
104. Clark DJ, Christou EA, Ring SA, Williamson JB, Doty L. Enhanced somatosensory feedback reduces prefrontal cortical activity during walking in older adults. J Gerontol A Biol Sci Med Sci. 2014;69:1422-1428. doi:10.1093/gerona/glu125
105. Holtzer R, Epstein N, Mahoney JR, Izzetoglu M, Blumen HM. Neuroimaging of mobility in aging: a targeted review. J Gerontol A Biol Sci Med Sci. 2014;69:1375-1388. doi:10.1093/gerona/glu052
106. Kim DH, Grodstein F, Newman AB, et al. Prognostic implications of microvascular and macrovascular abnormalities in older adults: cardiovascular health study. J Gerontol A Biol Sci Med Sci. 2014;69:1495-1502. doi:10.1093/gerona/glu074
107. Makizako H, Liu-Ambrose T, Shimada H, et al. Moderate-intensity physical activity, hippocampal volume, and memory in older adults with mild cognitive impairment. J Gerontol A Biol Sci Med Sci. 2015;70:480-486. doi:10.1093/gerona/glu136
108. Masser DR, Bixler GV, Brucklacher RM, et al. Hippocampal subregions exhibit both distinct and shared transcriptomic responses to aging and nonneurodegenerative cognitive decline. J Gerontol A Biol Sci Med Sci. 2014;69:1311-1324. doi:10.1093/gerona/glu091
109. Montero-Odasso M, Oteng-Amoako A, Speechley M, et al. The motor signature of mild cognitive impairment: results from the gait and brain study. J Gerontol A Biol Sci Med Sci. 2014;69:1415-1421. doi:10.1093/gerona/glu155
110. Nadkarni NK, Nunley KA, Aizenstein H, et al. Association between cerebellar gray matter volumes, gait speed, and information-processing ability in older adults enrolled in the Health ABC study. J Gerontol A Biol Sci Med Sci. 2014;69:996-1003. doi:10.1093/gerona/glt151
111. Rosano C, Rosso AL, Studenski SA. Aging, brain, and mobility: progresses and opportunities. J Gerontol A Biol Sci Med Sci. 2014;69:1373-1374. doi:10.1093/gerona/glu159
112. Rosso AL, Sanders JL, Arnold AM, et al. Multisystem physiologic impairments and changes in gait speed of older adults. J Gerontol A Biol Sci Med Sci. 2015;70:319-324. doi:10.1093/gerona/glu176
113. Sakurai R, Fujiwara Y, Yasunaga M, et al. Regional cerebral glucose metabolism and gait speed in healthy community-dwelling older women. J Gerontol A Biol Sci Med Sci. 2014;69:1519-1527. doi:10.1093/gerona/glu093
114. VanSwearingen JM, Studenski SA. Aging, motor skill, and the energy cost of walking: implications for the prevention and treatment of mobility decline in older persons. J Gerontol A Biol Sci Med Sci. 2014;69:1429-1436. doi:10.1093/gerona/glu153
115. Iliff JJ, Lee H, Yu M, et al. Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. J Clin Invest. 2013;123:1299-1309. doi:10.1172/JCI67677
116. Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med. 2012;4:147ra111. doi:10.1126/scitranslmed.3003748
117. Iliff JJ, Wang M, Zeppenfeld DM, et al. Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain. J Neurosci. 2013;33:18190-18199. doi:10.1523/JNEUROSCI. 1592-13.2013
118. Rangroo Thrane V, Thrane AS, Plog BA, et al. Paravascular microcirculation facilitates rapid lipid transport and astrocyte signaling in the brain. Sci Rep. 2013;3:2582. doi:10.1038/srep02582
119. Kress BT, Iliff JJ, Xia M, et al. Impairment of paravascular clearance pathways in the aging brain. Ann Neurol. 2014;76:845-861. doi:10.1002/ana.24271
120. Goosens KA, Sapolsky RM. Stress and glucocorticoid contributions to normal and pathological aging. In: Riddle DR, ed. Brain Aging: Models, Methods, and Mechanisms. Frontiers in Neuroscience. Boca Raton, FL: CRC Press; 2007.
121. Ashpole NM, Sanders JE, Hodges EL, Yan H, Sonntag WE. Growth hormone, insulin-like growth factor-1 and the aging brain. Exp Gerontol. 2015;68:76-81. doi:10.1016/j.exger.2014.10.002
122. Toth P, Tucsek Z, Tarantini S, et al. IGF-1 deficiency impairs cerebral myogenic autoregulation in hypertensive mice. J Cereb Blood Flow Metab. 2014;34:1887-1897. doi:10.1038/jcbfm.2014.156
123. Toth P, Tarantini S, Ashpole NM, et al. IGF-1 deficiency impairs neurovascular coupling in mice: implications for cerebromicrovascular aging. Aging Cell. 2015 doi:10.1111/acel.12372 [Epub ahead of print].
124. Sinha M, Jang YC, Oh J, et al. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science. 2014;344:649-652. doi:10.1126/science.1251152
125. Katsimpardi L, Litterman NK, Schein PA, et al. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science. 2014;344:630-634. doi:10.1126/science.1251141
126. Villeda SA, Luo J, Mosher KI, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011;477:90-94. doi:10.1038/nature10357
127. Villeda SA, Plambeck KE, Middeldorp J, et al. Young blood reverses agerelated impairments in cognitive function and synaptic plasticity in mice. Nat Med. 2014;20:659-663. doi:10.1038/nm.3569
128. Smith LK, He Y, Park JS, et al. beta2-microglobulin is a systemic proaging factor that impairs cognitive function and neurogenesis. Nat Med. 2015;21:932-937. doi:10.1038/nm.3898